Literature DB >> 24452167

Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Michael D Parkins1, Bryan A Glezerson, Christopher D Sibley, Kristen A Sibley, Jessica Duong, Swathi Purighalla, Christopher H Mody, Matthew L Workentine, Douglas G Storey, Michael G Surette, Harvey R Rabin.   

Abstract

Transmissible strains of Pseudomonas aeruginosa have been described for cystic fibrosis (CF) and may be associated with a worse prognosis. Using a comprehensive strain biobank spanning 3 decades, we sought to determine the prevalence and stability of chronic P. aeruginosa infection in an adult population. P. aeruginosa isolates from sputum samples collected at initial enrollment in our adult clinic and at the most recent clinic visit were examined by a combination of pulsed-field gel electrophoresis and multilocus sequence typing and compared against a collection of established transmissible and local non-CF bronchiectasis (nCFB) isolates. A total of 372 isolates from 107 patients, spanning 674 patient-years, including 66 patients with matched isolates from initial and final encounters, were screened. A novel clone with increased antibacterial resistance, termed the prairie epidemic strain (PES), was found in 29% (31/107 patients) of chronically infected patients referred from multiple prairie-based CF centers. This isolate was not found in those diagnosed with CF as adults or in a control population with nCFB. While 90% (60/66 patients) of patients had stable infection over a mean of 10.8 years, five patients experienced strain displacement of unique isolates, with PES occurring within 2 years of transitioning to adult care. PES has been present in our cohort since at least 1987, is unique to CF, generally establishes chronic infection during childhood, and has been found in patients at the time of transition of patients from multiple prairie-based CF clinics, suggesting broad endemicity. Studies are under way to evaluate the clinical implications of PES infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452167      PMCID: PMC3993468          DOI: 10.1128/JCM.03218-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  54 in total

1.  Emergence of a mutL mutation causing multilocus sequence typing-pulsed-field gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient.

Authors:  María García-Castillo; Luis Máiz; María-Isabel Morosini; Mercedes Rodríguez-Baños; Lucrecia Suarez; Ana Fernández-Olmos; Fernando Baquero; Rafael Cantón; Rosa del Campo
Journal:  J Clin Microbiol       Date:  2012-02-08       Impact factor: 5.948

2.  An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.

Authors:  S S Pedersen; C Koch; N Høiby; K Rosendal
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

3.  Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.

Authors:  Julia Emerson; Sharon McNamara; Anne Marie Buccat; Kelly Worrell; Jane L Burns
Journal:  Pediatr Pulmonol       Date:  2010-04

4.  Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections.

Authors:  Eilidh Mowat; Steve Paterson; Joanne L Fothergill; Elli A Wright; Martin J Ledson; Martin J Walshaw; Michael A Brockhurst; Craig Winstanley
Journal:  Am J Respir Crit Care Med       Date:  2011-02-04       Impact factor: 21.405

5.  Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.

Authors:  Richard Bradbury; Alan Champion; David W Reid
Journal:  Respirology       Date:  2008-11       Impact factor: 6.424

6.  Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

Authors:  K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

7.  Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.

Authors:  S S Pedersen; T Jensen; N Høiby; C Koch; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1987-11

8.  Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

Authors:  Samiya Razvi; Lynne Quittell; Ase Sewall; Hebe Quinton; Bruce Marshall; Lisa Saiman
Journal:  Chest       Date:  2009-06-08       Impact factor: 9.410

9.  Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in The Netherlands.

Authors:  R W Brimicombe; L Dijkshoorn; T J K van der Reijden; I Kardoes; T L Pitt; P J van den Broek; H G M Heijerman
Journal:  J Cyst Fibros       Date:  2007-05-25       Impact factor: 5.482

10.  Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis.

Authors:  C E Wainwright; M W France; P O'Rourke; S Anuj; T J Kidd; M D Nissen; T P Sloots; C Coulter; Z Ristovski; M Hargreaves; B R Rose; C Harbour; S C Bell; K P Fennelly
Journal:  Thorax       Date:  2009-07-01       Impact factor: 9.139

View more
  27 in total

Review 1.  Carbapenem-Resistant Non-Glucose-Fermenting Gram-Negative Bacilli: the Missing Piece to the Puzzle.

Authors:  Thomas J Gniadek; Karen C Carroll; Patricia J Simner
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

2.  The Pseudomonas aeruginosa Population among Cystic Fibrosis Patients in Quebec, Canada: a Disease Hot Spot without Known Epidemic Isolates.

Authors:  Julie Jeukens; Luca Freschi; Irena Kukavica-Ibrulj; Jean-Guillaume Emond-Rheault; Christian Allard; Jean Barbeau; André Cantin; Steve J Charette; Eric Déziel; François Malouin; Julie Milot; Dao Nguyen; Clara Popa; Brian Boyle; Roger C Levesque
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

3.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

4.  Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis.

Authors:  Mila M Almeida; Meyvianne T Freitas; Tania W Folescu; Monica C Firmida; Ana Paula D'A Carvalho-Assef; Elizabeth A Marques; Robson S Leão
Journal:  Curr Microbiol       Date:  2021-01-06       Impact factor: 2.188

5.  Potentiation of Tobramycin by Silver Nanoparticles against Pseudomonas aeruginosa Biofilms.

Authors:  Marc B Habash; Mara C Goodyear; Amber J Park; Matthew D Surette; Emily C Vis; Robert J Harris; Cezar M Khursigara
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 6.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

7.  Virulence adaptations of Pseudomonas aeruginosa isolated from patients with non-cystic fibrosis bronchiectasis.

Authors:  Taylor E Woo; Jessica Duong; Nicole M Jervis; Harvey R Rabin; Michael D Parkins; Douglas G Storey
Journal:  Microbiology       Date:  2016-12       Impact factor: 2.777

8.  Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Authors:  Muhammad-Hariri Mustafa; Hussein Chalhoub; Olivier Denis; Ariane Deplano; Anne Vergison; Hector Rodriguez-Villalobos; Michael M Tunney; J Stuart Elborn; Barbara C Kahl; Hamidou Traore; Francis Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  Development and Validation of a PCR Assay To Detect the Prairie Epidemic Strain of Pseudomonas aeruginosa from Patients with Cystic Fibrosis.

Authors:  M Workentine; A Poonja; B Waddell; J Duong; D G Storey; D Gregson; R Somayaji; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

Review 10.  Origin and Impact of Nitric Oxide in Pseudomonas aeruginosa Biofilms.

Authors:  Francesca Cutruzzolà; Nicole Frankenberg-Dinkel
Journal:  J Bacteriol       Date:  2016-01-01       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.